Structure of TAK-020

oral covalent BTK inhibitor

>80% BTK occupancy <5 mg (Ph. I dose esc.)

from fragment-based screen of 11k cmpds

Journal of Medicinal Chemistry

Takeda, San Diego, CA, USA

The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.